Loading…
Beijing-based pharmaceutical research and manufacturing company selling drugs in China.
Beijing-based pharmaceutical research and manufacturing company selling drugs in China.
Moat: none
Headquarters: Beijing, China · Employees: 1,335
Size Beijing Sun-Novo Pharmaceutical Research (688621.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $894M, the 2534th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥53.24 on 6 Nov 2026.
Performance Over six months the shares fell 7.7%, against -14.9% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue fell 0.6% over the last twelve months (peer median +1.3%); the operating margin is -1.8% (peer median 3.6%).
Valuation It trades at 30.6× forward earnings against a peer median of 26.0× (4th most expensive of 9).
Capital Return on invested capital runs 5.9 points below its cost of capital (7.8% WACC).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.01B | CN¥1.22B | CN¥1.08B | CN¥931M | CN¥676M |
| Revenue growth | — | +13% | +16% | +38% | — |
| Gross profit | CN¥550M | CN¥634M | CN¥512M | CN¥499M | CN¥358M |
| EBITDA | n/a | CN¥277M | CN¥241M | CN¥255M | CN¥208M |
| Net income | CN¥6.04M | CN¥204M | CN¥177M | CN¥185M | CN¥156M |
| Free cash flow | -CN¥161M | CN¥53.5M | CN¥4.39M | CN¥21.2M | CN¥2.71M |
| Capital expenditure | CN¥50.6M | CN¥42.4M | CN¥30.5M | CN¥73.0M | CN¥104M |
| Total debt | CN¥713M | CN¥613M | CN¥457M | CN¥448M | CN¥259M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688621.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.4% | -6.6% | 2nd lowest of 20 |
| 6-month return | -7.7% | -14.9% | 7th highest of 20 |
| Distance from 52-week high | -34.0% | -35.3% | 11th highest of 21 |
| Revenue growth (TTM) | -0.6% | +1.3% | 9th lowest of 19 |
| Operating margin | -1.8% | 3.6% | 7th lowest of 19 |
| Forward P/E | 30.6× | 26.0× | 4th most expensive of 9 |
| ROIC minus cost of capital | -5.9 pp | -2.2 pp | 5th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $894M | -8% | -1% | -2% | 30.6× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $893M | -27% | +1% | 0% | n/a | n/a | n/a |
| Aarti Pharmalabs AARTIPHARM.NS | India | $892M | +19% | +13% | 18% | n/a | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $887M | -32% | n/a | n/a | n/a | n/a | n/a |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | n/a | 16.2% | -0.2% |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | n/a | -1.2% | -39.5% |
| Aktis Oncology AKTS | United States | $880M | -15% | +337% | -1,150% | n/a | n/a | n/a |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $909M | -33% | -14% | -29% | n/a | n/a | n/a |
| Bide Pharmatech 688073.SS | China | $912M | +5% | +10% | 19% | 27.5× | 16.7% | +27.7% |
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $874M | -30% | +9% | 12% | 5.8× | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $874M | -2% | +2% | 9% | 41.4× | 2.5% | +12.4% |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | n/a | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $861M | -7% | +2% | 14% | 11.0× | 4.8% | +22.5% |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 41.1× | 33.2% | +4.2% |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 24.5× | 16.2% | +27.3% |
| Kaken Pharmaceutical 4521.T | Japan | $854M | -8% | -7% | 11% | 24.5× | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 33.8× | n/a | n/a |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | n/a | -6.8% | -0.7% |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | n/a | n/a | n/a |